BioCryst Pharmaceuticals Reports Q1 2026 Earnings Call Details

BioCryst Pharmaceuticals reported strong performance in its first-quarter earnings call, with ORLADEYO net revenue reaching $148.3 million and the ALPHA-ORBIT trial for navenibart exceeding enrollment expectations. The company maintained full-year 2026 guidance of $625–$645 million for ORLADEYO despite a manufacturing delay affecting pediatric pellets.

By Moby Intelligence Wed, May 6, 2026 at 7:48 PM GMT+3 3 min read · Yahoo Finance · May 6, 2026, 16:48 UTC

Tickers: $BCRX

Topics: clinical trials pharmaceuticals R&D strategy revenue guidance

Read the full article at Yahoo Finance

More World news

Nvidia CEO Jensen Huang Ousted Amid Allegations of Personal Misconduct and National Security Concerns TechCrunch · November 12, 2026, 16:32 UTC
Pomerantz Law Firm Investigates Silvercorp Metals Inc. Following Production Shortfalls and Revenue Decline PR Newswire · November 12, 2026, 16:30 UTC
Cold Spring Harbor Laboratory Raises $6.5 Million at 21st Annual Double Helix Medals Dinner PR Newswire · November 12, 2026, 16:30 UTC
Deloitte Recognized as Leader in IDC MarketScape Worldwide Digital Identity Services Assessment PR Newswire · November 12, 2026, 16:30 UTC
SpaceX Announces $74 Billion Investment in AI Data Center Projects in Texas and Arizona Seeking Alpha · November 12, 2026, 16:25 UTC
Ofcom Fines Meta £450,000 Over Inaccurate WhatsApp Business Data Seeking Alpha · November 12, 2026, 16:25 UTC
USPS Seeks 11% Fuel Surcharge for Domestic Priority Mail and Package Deliveries CNBC · November 12, 2026, 16:17 UTC
Joe Lavis Named to D CEO's 2027 Dallas 500 List PR Newswire · November 12, 2026, 16:26 UTC
Sanmina Corporation (SANM) Shares Rise 8% Amid Five-Day Winning Streak Seeking Alpha · November 12, 2026, 16:23 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal and National Security Concerns Motley Fool · November 12, 2026, 16:17 UTC